Overview
- Editors:
-
-
Khalid El Bairi
-
Cancer Biomarkers Working Group, Oujda, Morocco
Summarizes the etiology and pathogenesis of ovarian cancer
Highlights the implications of prognostic and diagnostic markers for precision medicine
Reviews the role of deep molecular and cellular profiling for the identification of potential therapeutic targets
Access this book
Other ways to access
Table of contents (7 chapters)
-
-
- Sara Nasser, Khalid El Bairi, Dario Trapani, Boubacar Efared
Pages 1-17
-
- Emilio Francesco Giunta, Annalisa Pappalardo, Dario Trapani, Angelica Petrillo
Pages 19-57
-
- Khalid El Bairi, Ouissam Al Jarroudi, Said Afqir
Pages 59-133
-
- Khalid El Bairi, Ouissam Al Jarroudi, Said Afqir
Pages 135-166
-
- Khalid El Bairi, Ouissam Al Jarroudi, Laura Carpenito, Dario Trapani, Said Afqir
Pages 167-185
-
- Marco Petrillo, Carlo Ronsini, Davide Calandra, Margherita Dessole, Salvatore Dessole
Pages 187-202
-
- Alia Ghoneum, Amal Tazzite, Khalid El Bairi, Neveen Said
Pages 203-229
About this book
This book comprehensively summarizes the biology, etiology, and pathology of ovarian cancer and explores the role of deep molecular and cellular profiling in the advancement of precision medicine. The initial chapter discusses our current understanding of the origin, development, progression and tumorigenesis of ovarian cancer. In turn, the book highlights the development of resistance, disease occurrence, and poor prognosis that are the hallmarks of ovarian cancer. The book then reviews the role of deep molecular and cellular profiling to overcome challenges that are associated with the treatment of ovarian cancer. It explores the use of genome-wide association analysis to identify genetic variants for the evaluation of ovarian carcinoma risk and prognostic prediction. Lastly, it highlights various diagnostic and prognostic ovarian cancer biomarkers for the development of molecular-targeted therapy.
Editors and Affiliations
-
Cancer Biomarkers Working Group, Oujda, Morocco
Khalid El Bairi
About the editor
Khalid El Bairi is the principal investigator of OVANORDEST studies and the founder of The Cancer Biomarkers Working Group, and he is currently pursuing clinical and translational research in medical oncology. He has published many peerreviewed articles in the field of predictive and prognostic cancer biomarkers to improve survival outcomes in several WoS and Medline-indexed journals. His research focuses particularly on biomarkers for digestive and gynecological cancers such as ovarian and colorectal malignancies. He is currently a member of the board of various international scientific societies such as the International Gynecologic Cancer Society (IGCS), European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), European Society of Gynaecological Oncology (ESGO), and the American Association for Cancer Research (AACR). He is also an editor and reviewer for more than 40 academic journals and a guest editor for several special issues on emerging topics in gynecological cancers such as platinum-resistant ovarian cancer. He is also highly interested in teaching evidence-based medicine, clinical research methods, and publishing ethics to medical and PhD students and was selected for the 70th Lindau Nobel Laureate Meeting as a young scientist.
